Well yes of course when considering any stock "it behooves" (love the almost Victorian turn of phrase, school-master superiority points for that) one to examine the chances of success or failure. For biotechs the first question is do you think the science is correct and is it scaleable for mass production, Then come questions of market size, the ability of the company to navigate the regulatory maze, the ability to secure funding from whatever source to push through to approval and finally marketing a product. And as the link above shows even if the company is successful they will, on average after 15 years still not be at the stage of self sustaining commercialisation.
I think your comments demonstrate that you lack any expertise in investing in biotech, or any other early stage company with a strong science focus.
Well yes of course when considering any stock "it behooves"...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.020(1.73%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.17 | $16.67M | 14.04M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 54704 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.020 ( 3.40 %) |
||||
| Open | High | Low | Volume | ||
| $1.21 | $1.21 | $1.17 | 2927691 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| MSB (ASX) Chart |